Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes
GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amount of convertible senior notes due 2027 (the "notes"). The notes will be offered and sold...
Siemens Earns the Frost & Sullivan 2022 Company of the Year Award for Its Pioneering Approach in the Data Center Industry
Siemens delivers a cost-effective and scalable ecosystem that significantly improves data center operators' performance. SAN ANTONIO, Dec. 15, 2022 /PRNewswire/ -- Based on its recent analysis of the workforce engagement and intelligent automation industry, Frost & Sullivan recognizes Siemens with the 2022 Company of the Year Award for its innovative and leading approach in the...
Lunit AI Can Help Tuberculosis Screening in Prisons, as Published in The Lancet Regional Health – Americas
Recent study suggests that AI-based x-ray interpretation algorithms may be an efficient means to improve TB case detection among incarcerated populations Lunit INSIGHT CXR showed the most superior performance among the tested cohort, with greater accuracy and generalizability among subgroups SEOUL, South Korea, Dec. 15, 2022 /PRNewswire/ -- Findings from a...
China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19
HAIKOU, China, Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 (First Edition) (hereinafter referred to as the Catalogue) published...
BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy
A leader in creating jobs through the advancement of RNA-based therapeutics A contributor to a high employment rate in Korea's healthcare industry BOSTON, Dec. 15, 2022 /PRNewswire/ -- BIORCHESTRA ("BIORCHESTRA" or the "Company"), a RNA therapeutics company with offices in Daejeon, South Korea, and Cambridge, Massachusetts, USA and focused on neurodegenerative and rare...
Duality announced the appointment of Dr. Pasi A. Jänne as Member of SAB
PRINCETON, N. J., SHANGHAI and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Duality Biotherapeutics, Inc. ("Duality" or "the Company") today announced the appointment of Dr. Pasi A. Jänne as member of SAB. Dr. Jänne will provide strategic advice and guidance for the Company's clinical and translation medicine strategy development to elevate the Company's innovation in the field of Antibody Drug...
Nevisense for skin barrier evaluation included in large Australian birth cohort study
STOCKHOLM, Dec. 15, 2022 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that SciBase has received an order for skin barrier assessment products to be included in one of the world's largest cohort studies - The ORIGINS Project, which is a collaboration between Joondalup Health Campus and Telethon Kids...
Infermedica Celebrates Record Year, Accelerating Momentum Into 2023
$30M Series B funding round, launch of Medical Guidance Platform, and inclusion in CB Insights' Digital Health 150 list mark just some of the achievements in the 10th year since the company's founding DENVER, Dec. 15, 2022 /PRNewswire/ -- Infermedica – a leading digital health company specializing in AI-powered solutions for symptom analysis,...
International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children’s Cancers
ACC, NCCN, ACS, and CHAI collaborate to launch new NCCN Harmonized Guidelines for Sub-Saharan Africa focused on pediatric cancers; available free at NCCN.org/harmonized. DAR ES SALAAM, Tanzania and PLYMOUTH MEETING, Pa., Dec. 15, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—is working...
Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Phase II/III randomized, controlled trial LEIDEN, Netherlands,...
